TY - JOUR
T1 - Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature
AU - Benucci, Maurizio
AU - Saviola, Gianantonio
AU - Manfredi, Mariangela
AU - Sarzi-Puttini, Piercarlo
AU - Atzeni, Fabiola
PY - 2011
Y1 - 2011
N2 - The cost effectiveness of treatments that have changed the "natural history" of a chronic progressive disease needs to be evaluated over the long term. Disease-modifying antirheumatic drugs (DMARDs) are the standard treatment of rheumatoid arthritis (RA) and should be started as early as possible. A number of studies have shown that they are effective in improving disease activity and function, and in joint damage. Our review was focused on revision and critical evaluation of the studies including the literature on cost effectiveness of DMARDs (cyclosporine A, sulphasalazine, leflunomide, and methotrexate). The European League Against Rheumatism (EULAR) recommendations showed that traditional DMARDs are cost effective at the time of disease onset. They are less expensive than biological DMARDs and can be useful in controlling disease activity in early RA.
AB - The cost effectiveness of treatments that have changed the "natural history" of a chronic progressive disease needs to be evaluated over the long term. Disease-modifying antirheumatic drugs (DMARDs) are the standard treatment of rheumatoid arthritis (RA) and should be started as early as possible. A number of studies have shown that they are effective in improving disease activity and function, and in joint damage. Our review was focused on revision and critical evaluation of the studies including the literature on cost effectiveness of DMARDs (cyclosporine A, sulphasalazine, leflunomide, and methotrexate). The European League Against Rheumatism (EULAR) recommendations showed that traditional DMARDs are cost effective at the time of disease onset. They are less expensive than biological DMARDs and can be useful in controlling disease activity in early RA.
UR - http://www.scopus.com/inward/record.url?scp=84855585686&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855585686&partnerID=8YFLogxK
U2 - 10.1155/2011/845496
DO - 10.1155/2011/845496
M3 - Article
C2 - 22162693
AN - SCOPUS:84855585686
VL - 2011
JO - International Journal of Rheumatology
JF - International Journal of Rheumatology
SN - 1687-9260
M1 - 845496
ER -